Skip to main content

PExA enters into a research collaboration agreement with Janssen and the University of Gothenburg for discovery of biomarkers in exhaled air

Pressmeddelande   •   Okt 04, 2019 12:47 CEST

Swedish medical technology company PExA AB (“PExA”) announced that it has entered into a research collaboration agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the University of Gothenburg.

PExA, which focuses on the development and commercialization of a unique breath sampling technology for biomarker discovery, was recently selected Awardee of the Carcinogenic Exposure Meter Quickfire Challenge. The Challenge was launched by Johnson & Johnson Innovation, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen in an effort to help reduce the tobacco epidemic.

As part of the collaboration, Janssen will fund the assessment of clinical PEx-samples to identify biomarker categories that potentially can detect carcinogenic damage resulting from tobacco exposure.

Erik Ekbo, CEO of PExA comments on the agreement:

“Collaborating with one of the world’s most innovative pharmaceutical companies provides a significant step forward in our transformation journey to deliver novel solutions suitable for point-of-care testing.”

For further information, please contact:

Erik Ekbo, CEO
Phone: +46 723-92 30 30 E-mail:

This information is information which PExA AB is obligated to publish under the EU Market Abuse Regulation. The information was provided through the agency of above contact person, for publication on October 2, 2019.

PExA AB (556956-9246) develops and markets a research instrument with associated products and services to respiratory researchers for easy and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be compared to a "blood test for the small airways ". The aim is to facilitate the development of reliable and more individualized diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventor, key employees, business angels and GU Ventures. The company's B-shares are listed on Spotlight Stock Market. 

Om GU Ventures

GU Ventures är topprankad av UBI Global som en av världens 20 främsta universitetsstyrda inkubatorer. Sedan starten 1995 har GU Ventures utvecklat 150 nya affärsidéer. Portföljen består idag av 55 innehav, varav nio är noterade. 87% av företagen i portföljen bidrar till de globala hållbarhetsmålen som fastställts av FN.

GU Ventures är helägt av svenska staten och förvaltas av Göteborgs universitet. Uppdraget är att finansiera och utveckla nya affärer och företag med anknytning till Göteborgs universitet, vilket leder till nyttiggörande av forskning och kompetens, förnyelse av näringslivet, jobbskapande och hållbar tillväxt. Läs gärna mer på:

GU Ventures sprider nyheter och information kring verksamheten, bolag i portföljen samt alumni.